{"success":true,"data":{"pressRelease":{"id":"17137","rtpr_id":"nGNX7pGNnh","ticker":"NSRX","exchange":"NYSE American","all_tickers":["NSRX"],"title":"Nasus Pharma to Participate in Upcoming Investor Conferences ","author":"Globe Newswire","published_at":"2026-05-01T13:14:03.337Z","article_body":"TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:\nNSRX) (\"Nasus Pharma\" or the \"Company\"), a clinical-stage pharmaceutical\ncompany focused on the development of innovative intranasal products, today\nannounced that Company management will participate in upcoming investor\nconferences. \n\nMarket Movers Investor Summit\nMay 5, 2026, New York, NY\nChief Financial Officer Eyal Rubin will participate in 1x1 meetings. \n\nD. Boral Capital Global Conference\nMay 7, 2026, New York, NY\nChief Financial Officer Eyal Rubin will participate in 1x1 meetings. \n\nInterested investors should contact their respective representatives at the\nsponsoring institutions to request meetings.\n\nAbout Nasus Pharma\nNasus Pharma is a clinical-stage pharmaceutical company developing a number of\nintranasal powder products addressing acute medical conditions in the\ncommunity. NS002, Nasus Pharma’s intranasal powder Epinephrine product\ncandidate is being developed as a needle-free alternative to Epinephrine\nautoinjectors for patients with anaphylaxis. Intranasal administration is most\nsuitable for those situations in which rapid drug delivery is required and\noffers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary\npowder-based intranasal (“PBI”) technology is designed for rapid and\nreliable drug delivery, leveraging the nasal cavity’s rich vascular network\nfor quick absorption. The PBI formulation uses uniform spherical powder\nparticles for broad dispersion and potentially faster, higher absorption\ncompared to liquid-based nasal products. For further information about the\nCompany, please visit www.nasuspharma.com or follow on Twitter (X) or\nLinkedIn.\n\nCompany Contact\nNasus Pharma Ltd.\ninfo@nasuspharma.com\n\nInvestor Contact\nMike Moyer\nLifeSci Advisors\n+1-617-308-4306\nmmoyer@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/635331e1-7b05-412a-b2db-eebfda31ae81)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7pGNnh","title":"Nasus Pharma to Participate in Upcoming Investor Conferences ","author":"Globe Newswire","ticker":"NSRX","created":"2026-05-01T13:14:03.337Z","tickers":["NSRX"],"exchange":"NYSE American","article_body":"TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE:\nNSRX) (\"Nasus Pharma\" or the \"Company\"), a clinical-stage pharmaceutical\ncompany focused on the development of innovative intranasal products, today\nannounced that Company management will participate in upcoming investor\nconferences. \n\nMarket Movers Investor Summit\nMay 5, 2026, New York, NY\nChief Financial Officer Eyal Rubin will participate in 1x1 meetings. \n\nD. Boral Capital Global Conference\nMay 7, 2026, New York, NY\nChief Financial Officer Eyal Rubin will participate in 1x1 meetings. \n\nInterested investors should contact their respective representatives at the\nsponsoring institutions to request meetings.\n\nAbout Nasus Pharma\nNasus Pharma is a clinical-stage pharmaceutical company developing a number of\nintranasal powder products addressing acute medical conditions in the\ncommunity. NS002, Nasus Pharma’s intranasal powder Epinephrine product\ncandidate is being developed as a needle-free alternative to Epinephrine\nautoinjectors for patients with anaphylaxis. Intranasal administration is most\nsuitable for those situations in which rapid drug delivery is required and\noffers needle-free, easy-to-use alternatives. Nasus Pharma’s proprietary\npowder-based intranasal (“PBI”) technology is designed for rapid and\nreliable drug delivery, leveraging the nasal cavity’s rich vascular network\nfor quick absorption. The PBI formulation uses uniform spherical powder\nparticles for broad dispersion and potentially faster, higher absorption\ncompared to liquid-based nasal products. For further information about the\nCompany, please visit www.nasuspharma.com or follow on Twitter (X) or\nLinkedIn.\n\nCompany Contact\nNasus Pharma Ltd.\ninfo@nasuspharma.com\n\nInvestor Contact\nMike Moyer\nLifeSci Advisors\n+1-617-308-4306\nmmoyer@lifesciadvisors.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/635331e1-7b05-412a-b2db-eebfda31ae81)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-01T13:14:03.376755053Z","server_sent_at_ms":1777641243376},"received_at":"2026-05-01T13:14:03.436Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}